TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 347870

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Placebo gel
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Steradent
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Placebo solution
Number of subjects: 74
Study: 31678069

Group type: EXPERIMENTAL
Intervention: Ingestion of 170g pork loin (36g protein, 5g fat)
Number of subjects: 30
Study: 31113205

Group type: EXPERIMENTAL
Intervention: Nurse-led structured education program
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (managed as per clinical guidelines without structured education)
Number of subjects: 96
Study: 28103850

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 120
Study: 26016866

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ) 340 mL/d providing 210 mg naringenin glycosides
Number of subjects: 48

Group type: COMPARATOR
Intervention: Matched control drink without flavanones
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 48
Study: 23490394

Group type: EXPERIMENTAL
Intervention: Dynamic treatment (DT) for 24‐72 weeks based on viral decline rates
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard of care (SOC) for 24, 48 or 72 weeks
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Dynamic treatment (DT)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Dynamic treatment (DT) among patients who achieved undetectable HCV RNA
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard of care (SOC) among patients who achieved undetectable HCV RNA
Number of subjects: 103
Study: 21733046

Group type: EXPERIMENTAL
Intervention: Incentive of 1 month of free treatment every fourth month of regularly respected visits (Group 2)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Reminder letters for missed follow-up visits (Group 3)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control group (Group 1) with no additional intervention
Number of subjects: 221
Study: 19592595

Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 200 microg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 400 microg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 800 microg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17229426

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg/day
Number of subjects: 871

Group type: COMPARATOR
Intervention: Atorvastatin 80 mg/day
Number of subjects: 871
Study: 16104943

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication (active group, n = 9)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (control group, n = 11)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Active eradication (blind or open)
Number of subjects: 56
Study: 12924797

Group type: EXPERIMENTAL
Intervention: Vaccine group (received intramuscular injection with purified trivalent split‐virus vaccine)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo group (received intramuscular injection with vit B1)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Vaccine group (mild COPD)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo group (mild COPD)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Vaccine group (moderate COPD)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo group (moderate COPD)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Vaccine group (severe COPD)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo group (severe COPD)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Vaccine group (all COPD patients)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Vaccine group (patients with severe airflow obstruction)
Number of subjects: 125
Study: 10396014

Group type: EXPERIMENTAL
Intervention: Hypnosis with active suggestions of improvement
Number of subjects: 11

Group type: COMPARATOR
Intervention: Neutral hypnosis with no mention of disease process
Number of subjects: 11
Study: 8634222

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (administered over a 4-8 week period)
Number of subjects: 40
Study: 1962780

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (cisplatin and vinblastine) followed by radiotherapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 180
Study: 6115521

Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol (acute beta 1-adrenergic blockade)
Number of subjects: 14
Study: 29534456

Group type: EXPERIMENTAL
Intervention: Insect protein isolate
Number of subjects: 18

Group type: COMPARATOR
Intervention: Isocaloric carbohydrate supplementation
Number of subjects: 18
Study: 27089159

Group type: EXPERIMENTAL
Intervention: CT+Memory Support
Number of subjects: 48

Group type: COMPARATOR
Intervention: CT-as-usual
Number of subjects: 48
Study: 23928139

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced FIESTA
Number of subjects: 29

Group type: COMPARATOR
Intervention: Contrast-enhanced T1WI
Number of subjects: 29

Group type: COMPARATOR
Intervention: Contrast-enhanced T2WI
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Solid-type adenomas
Number of subjects: 29
Study: 22796247

Group type: EXPERIMENTAL
Intervention: FF Rotadisk 100 μg once daily in the morning
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: FF Rotadisk 100 μg once daily in the evening
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: FF Rotadisk 250 μg once daily in the evening
Number of subjects: 575

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 575
Study: 20090429

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study: 18558697

Group type: EXPERIMENTAL
Intervention: Cranberry Juice (CJ)
Number of subjects: 10

Group type: COMPARATOR
Intervention: High Fructose Corn Syrup (HFCS)
Number of subjects: 10
Study: 16187917

Group type: EXPERIMENTAL
Intervention: 30 mg of octreotide-LAR every 4 weeks for 16 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 12117048

Group type: EXPERIMENTAL
Intervention: Fibreoptic bronchoscopy (FOB) with local Lignocaine anaesthesia
Number of subjects: 57
Study: 10412894

Group type: EXPERIMENTAL
Intervention: Cardioxane (dexrazoxane hydrochloride salt)
Number of subjects: 15

Group type: COMPARATOR
Intervention: ICRF‐187 (dexrazoxane base)
Number of subjects: 15
Study: 7585851

Group type: EXPERIMENTAL
Intervention: Roxatidine (150 mg)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Ranitidine (300 mg)
Number of subjects: 620
Study: 2223741

Group type: EXPERIMENTAL
Intervention: High protein diet enriched with fat (HP/F)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High protein diet enriched with carbohydrate (HP/C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low protein diet enriched with fat (LP/F)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low protein diet enriched with carbohydrate (LP/C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low protein diets (LP)
Number of subjects: 0
Study: 7384769

Group type: EXPERIMENTAL
Intervention: Glucose syrup ingestion in the morning
Number of subjects: 57

Group type: COMPARATOR
Intervention: High energy intake (mean 15 MJ or 3,600 kcal)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Alcohol intake (1 to 2 MJ or 240 to 480 kcal)
Number of subjects: 57
Study: 31373978

Group type: EXPERIMENTAL
Intervention: Traditional crunch
Number of subjects: 15

Group type: COMPARATOR
Intervention: 5-minute Shaper device
Number of subjects: 15
Study: 31561490

Group type: EXPERIMENTAL
Intervention: Western diet high-fat (WD) with moderate walking (4.6 ± 0.1 km/h)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Western diet high-fat (WD) with rest
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Mediterranean-type diet (MD) with moderate walking (4.6 ± 0.1 km/h)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Mediterranean-type diet (MD) with rest
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 26
Study: 28504033

Group type: EXPERIMENTAL
Intervention: Salvage chemotherapy (dexamethasone, cytarabine, cisplatin)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant
Number of subjects: 59

Group type: COMPARATOR
Intervention: Comparison to B-cell lymphoma
Number of subjects: 59
Study: 25844857

Group type: EXPERIMENTAL
Intervention: Short-wave diathermy (SWD) heat treatment for 40 minutes
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (rest without SWD)
Number of subjects: 15
Study: 23685295

Group type: EXPERIMENTAL
Intervention: Immediate invasive strategy (angiography and revascularisation <12 hr)
Number of subjects: 542

Group type: COMPARATOR
Intervention: Delayed invasive strategy (>48 hr after randomisation)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Immediate invasive strategy
Number of subjects: 542

Group type: COMPARATOR
Intervention: Delayed invasive strategy
Number of subjects: 542
Study: 21530722

Group type: EXPERIMENTAL
Intervention: 12-week program of combined exercise and dietary advice
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 18
Study: 19842561

Group type: EXPERIMENTAL
Intervention: Dressing composed of alginate + cotton pad
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Dressing composed of vaseline gauze + cotton pad
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Dressing composed of alginate + foam dressing
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Dressing composed of vaseline gauze + foam dressing
Number of subjects: 186
Study: 16676705

Group type: EXPERIMENTAL
Intervention: Chocolate milk
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fluid replacement drink (FR)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Carbohydrate replacement drink (CR)
Number of subjects: 9
Study: 14670772

Group type: EXPERIMENTAL
Intervention: Constipated children (30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: First degree relatives of constipated children (30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control children (30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: First degree relatives of control children (30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Relatives of arch positive children (6)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Relatives of arch negative children (54)
Number of subjects: 90
Study: 10703777

Group type: EXPERIMENTAL
Intervention: IV tPA therapy
Number of subjects: 3948

Group type: COMPARATOR
Intervention: Not receiving tPA
Number of subjects: 3948
Study: 8792483

Group type: EXPERIMENTAL
Intervention: 3-component DTaP vaccine
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 2-component DTaP vaccine
Number of subjects: 158

Group type: COMPARATOR
Intervention: DTwP vaccine
Number of subjects: 158
Study: 1514322

Group type: EXPERIMENTAL
Intervention: Wake time between 8.00 to 11.00 a.m.
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Wake time during the initial 3 hours after awakening
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: ADP threshold concentration in 10 patients with CAD
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Epinephrine threshold concentration in 10 patients with CAD
Number of subjects: 573
Study: 6335343

Group type: EXPERIMENTAL
Intervention: Metoprolol group (last metoprolol dose given 1.5 h before the anaesthesia)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (last metoprolol dose 12 h before the anaesthesia)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoprolol group
Number of subjects: 20
Study: 31084656

Group type: EXPERIMENTAL
Intervention: Nutrition education programme (NEP) for 12 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Brochure on nutrition guidelines for ALH (Control)
Number of subjects: 200
Study: 28935614

Group type: EXPERIMENTAL
Intervention: Air-filtration intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improved-technology woodstove intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26032211

Group type: EXPERIMENTAL
Intervention: 200 IU of intranasal salmon calcitonin daily for 3 months
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 24062391

Group type: EXPERIMENTAL
Intervention: Rituximab plus CHOP
Number of subjects: 292

Group type: COMPARATOR
Intervention: CHOP without Rituximab
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Radiotherapy to sites of skeletal involvement
Number of subjects: 292

Group type: COMPARATOR
Intervention: Rituximab (MInT and RICOVER-60 studies)
Number of subjects: 292
Study: 21804061

Group type: EXPERIMENTAL
Intervention: Lozenges containing anti-CA-gtf IgY
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 19390525

Group type: EXPERIMENTAL
Intervention: 10% energy restriction (ER)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 30% energy restriction (ER)
Number of subjects: 38
Study: 16650295

Group type: EXPERIMENTAL
Intervention: Allopurinol (100 mg tds for 3 months) with ofloxacin (200 mg tds for 3 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo tablets with ofloxacin (200 mg tds for 3 weeks)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 14647985

Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy with nanocolloids (NC) injected in a peritumoral site (group I)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy with nanocolloids (NC) injected in a subdermal site (group II)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Sole injection of NC into the lesion (group III)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Combination of ROLL procedure with direct injection of MAA into the lesion and lymphoscintigraphy with subdermal injection of radiocolloids
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Intraoperative examination of SNs
Number of subjects: 227
Study: 11707007

Group type: EXPERIMENTAL
Intervention: Etidronate (400 mg/d cyclically for 14 days with 76-day intervals, plus calcium and vitamin D)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/d daily)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Alendronate with HRT
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Etidronate without HRT
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 99
Study: 10346656

Group type: EXPERIMENTAL
Intervention: Incentive-competition program (multicomponent program + cash incentives + team competition)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Multicomponent program (self-help package + telephone counseling + other elements)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Traditional program (standard smoking cessation program)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Incentive-competition program
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Multicomponent program
Number of subjects: 185

Group type: COMPARATOR
Intervention: Traditional program
Number of subjects: 185
Study: 8006837

Group type: EXPERIMENTAL
Intervention: Artificial crowns with sintered noble metal margins (Degusint U)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Artificial crowns with cast noble metal margins (Degudent U)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Adjacent natural teeth
Number of subjects: 12
Study: 2521086

Group type: EXPERIMENTAL
Intervention: Apomorphine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1096666

Group type: EXPERIMENTAL
Intervention: Intravenous hyoscine butylbromide (Buscopan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atropine sulphate
Number of subjects: 0
Study: 27503036

Group type: EXPERIMENTAL
Intervention: MRA + forum
Number of subjects: 142

Group type: COMPARATOR
Intervention: MRA alone
Number of subjects: 142

Group type: COMPARATOR
Intervention: Forum access alone
Number of subjects: 142
Study: 26223781

Group type: EXPERIMENTAL
Intervention: Culturally adapted brief motivational intervention (CA-BMI)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Non-adapted brief motivational intervention (NA-BMI)
Number of subjects: 300
Study: 24160205

Group type: COMPARATOR
Intervention: No liquids
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Plain water
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sports drinks (SD)
Number of subjects: 14
Study: 21471783

Group type: EXPERIMENTAL
Intervention: Abdominal extraperitoneal block (AEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient controlled analgesia (PCA)
Number of subjects: 0
Study: 18373526

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg (titrated to 5 mg or 20 mg based on efficacy and safety)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study: 16434427

Group type: EXPERIMENTAL
Intervention: Selective ET‐A antagonist, BQ‐123 (n = 8) at 1000 and 3000 nmol/min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Selective ET‐B antagonist, BQ‐788 (n = 8) at 100 and 300 nmol/min
Number of subjects: 16

Group type: COMPARATOR
Intervention: Matched saline placebo (n = 8)
Number of subjects: 16
Study: 12432293

Group type: EXPERIMENTAL
Intervention: Topical 0.3% nifedipine and 1.5% lidocaine ointment every 12 hours for 6 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Topical 1.5% lidocaine and 1% hydrocortisone acetate ointment
Number of subjects: 110
Study: 9872815

Group type: EXPERIMENTAL
Intervention: Intrapleural urokinase (UK)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 31
Study: 7726809

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for social phobia (used for both refusers and excluded subjects)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for social phobia (for acceptors)
Number of subjects: 0
Study: 2193461

Group type: EXPERIMENTAL
Intervention: Flutamide plus leuprolide (LHRH-agonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flutamide monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flutamide in combination with LHRH-agonist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Leuprolide plus flutamide
Number of subjects: 0
Study: 6988951

Group type: EXPERIMENTAL
Intervention: Doxycycline prophylaxis
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 100
Study: 6432398

Group type: EXPERIMENTAL
Intervention: DL-Threo-3,4-dihydroxyphenylserine (DL-DOPS) 600 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: DL-Threo-3,4-dihydroxyphenylserine (DL-DOPS) 800 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: DL-Threo-3,4-dihydroxyphenylserine (DL-DOPS)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30580082

Group type: EXPERIMENTAL
Intervention: Duloxetine treatment (6-8 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment (6-8 weeks)
Number of subjects: 0
Study: 29319461

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waking state (Control)
Number of subjects: 32
Study: 26555870

Group type: EXPERIMENTAL
Intervention: 15 minutes of active air-forced warming after EDA and before induction of general anaesthesia (n=33)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Two periods of 15 minutes of active air-forced warming before and after EDA (n=34)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Passive insulation (control group, n=32)
Number of subjects: 99
Study: 24675683

Group type: EXPERIMENTAL
Intervention: Dieting implementation intentions (e.g., If I open the fridge I will think of dieting!)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Food go/no-go task (behavioral stop signals presented upon presentation of palatable foods)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control implementation intentions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control stimuli for go/no-go task
Number of subjects: 0
Study: 22269428

Group type: EXPERIMENTAL
Intervention: Enzastaurin plus cisplatin-pemetrexed (125 or 250 mg twice daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo plus cisplatin-pemetrexed
Number of subjects: 22
Study: 20844184

Group type: EXPERIMENTAL
Intervention: Irbesartan treatment
Number of subjects: 34
Study: 17623381

Group type: EXPERIMENTAL
Intervention: TRIP programme (n = 44)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Traditional ward occupational therapy (WOT) programme (n = 37)
Number of subjects: 81
Study: 16041193

Group type: EXPERIMENTAL
Intervention: Colesevelam HCl and ezetimibe combination therapy
Number of subjects: 12
Study: 11993618

Group type: EXPERIMENTAL
Intervention: Glycerol loading (1.2 g of glycerol per kg of body mass and 25 ml of a 0.75 g x kg(‐1) BM carbohydrate solution consumed over 60 minutes, 2 hours prior to ODT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glycerol loading
Number of subjects: 10
Study: 10568224

Group type: EXPERIMENTAL
Intervention: Alendronate plus calcium (10 mg alendronate + 500 mg calcium/day)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Alendronate plus calcitriol (0.25 microgram synthetic 1,25‐dihydroxyvitamin D3 + 10 mg alendronate)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Calcium (500 mg/day)
Number of subjects: 152
Study: 7725591

Group type: EXPERIMENTAL
Intervention: Tymoptin (T)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Sodium nucleinate (SN)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Prodigiosan (PR)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Combination of SN + PR
Number of subjects: 148

Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 148
Study: 2183488

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 75 mg intramuscular (im)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Baralgin 5 mL intravenous (iv)
Number of subjects: 57
Study: 7033848

Group type: EXPERIMENTAL
Intervention: Bromhexine hydrochloride (active group)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 195